Detalles de la búsqueda
1.
Combined, elobixibat, and colestyramine reduced cholesterol toxicity in a mouse model of metabolic dysfunction-associated steatotic liver disease.
Hepatol Commun;
7(11)2023 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37902528
2.
Natural History of Chronic Intestinal Pseudo-obstruction and Need for Palliative Care.
J Neurogastroenterol Motil;
29(3): 378-387, 2023 Jul 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37417265
3.
Comparison of long-term prognosis between non-obese and obese patients with non-alcoholic fatty liver disease.
JGH Open;
6(10): 696-703, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36262543
4.
Efficacy and safety of guanabenz acetate treatment for non-alcoholic fatty liver disease: a study protocol for a randomised investigator-initiated phase IIa study.
BMJ Open;
12(7): e060335, 2022 07 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35820743
5.
Rationale and design of a multicenter, single-group, open-label trial aiming at investigating the effectiveness of elobixibat for loss of defecation desire in patients with chronic constipation.
Contemp Clin Trials Commun;
28: 100958, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35812817
6.
Rationale and design of a multicentre, 12-week, randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated trial to investigate the efficacy and safety of elobixibat for chronic constipation.
BMJ Open;
12(5): e060704, 2022 05 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-35636802
7.
Effectiveness of Naldemedine Compared with Magnesium Oxide in Preventing Opioid-Induced Constipation: A Randomized Controlled Trial.
Cancers (Basel);
14(9)2022 Apr 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-35565243
8.
Association of Serum and Fecal Bile Acid Patterns With Liver Fibrosis in Biopsy-Proven Nonalcoholic Fatty Liver Disease: An Observational Study.
Clin Transl Gastroenterol;
13(7): e00503, 2022 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35616321
9.
Direct Comparison of US and MR Elastography for Staging Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Clin Gastroenterol Hepatol;
20(4): 908-917.e11, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33340780
10.
Endotoxins and Non-Alcoholic Fatty Liver Disease.
Front Endocrinol (Lausanne);
12: 770986, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34777261
11.
Protective effect of SGL5213, a potent intestinal sodium-glucose cotransporter 1 inhibitor, in nonalcoholic fatty liver disease in mice.
J Pharmacol Sci;
147(2): 176-183, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34384565
12.
The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target.
Int J Mol Sci;
22(15)2021 Jul 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-34360923
13.
Elobixibat Effectively Relieves Chronic Constipation in Patients with Cancer Regardless of the Amount of Food Intake.
Oncologist;
26(10): e1862-e1869, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34180099
14.
Vitamin B6 efficacy in the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, single-center trial.
J Clin Biochem Nutr;
68(2): 181-186, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33879971
15.
Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease.
J Gastroenterol Hepatol;
36(8): 2275-2284, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33709477
16.
Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial.
BMJ Open Diabetes Res Care;
9(1)2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33593749
17.
Case Reports: Transformation of End-Stage Neuroendocrine Tumors With Uncontrollable Liver Metastasis Into a Novel or Additional Functional Phenotype.
Front Oncol;
10: 555963, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33102220
18.
Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease.
BMJ Open;
10(9): e037961, 2020 09 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32907904
19.
Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial.
Lancet Gastroenterol Hepatol;
5(11): 996-1007, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32805205
20.
Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study.
Trials;
21(1): 453, 2020 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32487150